Related Experiment Video
Updated: Jul 7, 2026

07:51
Isolation of Leukocytes from the Murine Tissues at the Maternal-Fetal Interface
Published on: May 21, 2015
[Etanercept and pregnancy]
I Otermin1, G Elizondo, J Zabaleta
1Servicio de Medicina Interna, Clínica Ubarmin, Elcano, Navarra, Spain. inaki.otermin.maya@cfnavarra.es
Anales Del Sistema Sanitario De Navarra
|January 30, 2008
Abstract:
We present the case of a pregnant woman with arthritis in treatment with etanercept. After becoming pregnant she continued treatment with standard doses of this drug, 25 mg twice a week, without complications.
Related Concept Videos
Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...